Search

Displaying results 2961 - 2970 of 5506 in total
  1. Drug

    Oleoyl-estrone

    go.drugbank.com/drugs/DB04870
    Investigational

    It has been shown in animal studies to promote the loss of body fat while maintaining body protein storage, maintaining nitrogen balance.

  2. Drug

    Dronedarone

    go.drugbank.com/drugs/DB04855
    ApprovedInvestigational

    It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. … [A186071] It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.

  3. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

  4. Drug

    Hexoprenaline

    go.drugbank.com/drugs/DB08957
    ApprovedWithdrawn

    It is used as a bronchodilator, antiasthmatic, and tocolytic agent.

  5. Drug

    Laronidase

    go.drugbank.com/drugs/DB00090
    ApprovedInvestigational

    It contains 6 N-linked oligosaccharide modification sites. … The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase.

  6. Drug

    Alitretinoin

    go.drugbank.com/drugs/DB00523
    Approved

    It is used in the treatment of psoriasis; acne vulgaris; and several other skin diseases. It has also been approved for use in promyelocytic leukemia (leukemia, promyelocytic, acute).

  7. Drug

    Hesperetin

    go.drugbank.com/drugs/DB01094
    Investigational

    Hesperetin belongs to the flavanone class of flavonoids. Hesperetin, in the form of its glycoside hesperidin, is the predominant flavonoid in lemons and oranges.

  8. Drug

    Carindacillin

    go.drugbank.com/drugs/DB09319
    ApprovedWithdrawn

    It is no longer marketed in the United States.

  9. Drug

    Retapamulin

    go.drugbank.com/drugs/DB01256
    Approved

    It was approved by the FDA in April 2007.

  10. Drug

    KT-A261

    go.drugbank.com/drugs/DB19317
    Experimental

    KT-A261 is an adeno-associated viral vector serotype 2 (AAV2) encoded to express adalimumab. It is being investigated for the treatment of noninfectious uveitis.